MiNK Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
MiNK Therapeutics, Inc. (INKT) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $11.09 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2026-08-13
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2026-03-31 was $11.09.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2025 was $22.10.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $3.03, a 30200.00% increase from fiscal 2022.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $0.01, a 0.00% change from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.09 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $11.09 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $22.10 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $22.10 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $22.10 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-18 | |||
| 2023-12-31 | $3.03 10-K · filed 2024-03-21 | |||
| 2022-12-31 | $0.01 10-K · filed 2023-03-24 | |||
| 2022-09-30 | $0.01 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $0.01 10-Q · filed 2022-08-15 | |||
| 2021-12-31 | $0.01 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |